N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway
Inventors
Bhamra, Inder • Bingham, Matilda • Testar, Richard • Sargent, Louise • Donoghue, Craig
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This invention relates to compounds. More specifically, the invention relates to compounds useful as inhibitors of the Wnt signalling pathway. Specifically, inhibitors of Porcupine (Porcn) are contemplated by the invention. In addition the invention contemplates processes to prepare the compounds and uses of the compounds. The compounds of the invention may therefore be used in treating conditions mediated by the Wnt signalling pathway, for example treating cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia; or enhancing the effectiveness of an anti-cancer treatment.
Core Innovation
The disclosure relates to compounds of formula (I) and related scaffold formulas including formula (IVa), formula (IVb), formula (V), formula (Va), formula (Vb), and formula (Vc). It also relates to substituted pyrazole/pyrazolyl acetamide compounds, biaryl alpha-chloroacetamide-type compounds, N-pyridinyl acetamide derivatives, substituted N-(2-pyridyl/pyrimidinyl/pyrazinyl) acetamides, and substituted diamino/heteroaryl acetamide compounds with pyrazole-1-yl, imidazole, thienyl, and trifluoromethyl-pyridyl fragments.
The described chemical matter includes heteroaryl substituents, pyrazole substituents, pyridyl, pyrimidyl, pyrazinyl, and trifluoromethyl groups, together with pharmaceutically acceptable salts and related compound forms. The disclosure further includes pharmaceutical formulation elements and broad definitions for compound variants, together with example compounds, intermediates, and characterization data such as LC-MS, MS, NMR, LCMS/MS, LCMS, MS [M+H], LC-MS retention times, and 1H NMR chemical shifts.
The invention includes compounds described as Porcupine inhibitors to suppress Wnt/beta-catenin signaling and modulate Wnt signalling by Porcn inhibition. The document also describes synthetic intermediates and final examples, including labeled intermediates and analogous products with varied pyridine, pyrimidine, pyrazine, pyrazole, imidazole, and related heteroaryl substitution patterns.
The disclosed purpose is therapeutic use in treating a defined set of conditions, including cancer and other enumerated diseases, and in enhancing anti-cancer treatment for Wnt-mediated conditions. The document also states aims of improved activity and solubility, reduced cytotoxicity, convenient PK, and GRAS metabolites.
Claims Coverage
The provided claim coverage centers on compound claims, pharmaceutical composition claims, and method-of-treatment claims. Across the independent claims, the main inventive features are the defined compound or pharmaceutically acceptable salt, formulation into a pharmaceutical composition with pharmaceutically acceptable adjuvant, diluent, or carrier, and administration of a therapeutically effective amount to treat explicitly listed disease groups; the claim coverage also includes compound claims within the general formula framework and claims directed to Porcn inhibition and Wnt signalling modulation.
Compound of formula (I) and pharmaceutically acceptable salts
A compound of formula (I) and a pharmaceutically acceptable salt thereof.
N-pyridinyl acetamide Porcupine inhibitor compound
A compound of the described subject matter, or a pharmaceutically acceptable salt thereof.
Substituted amide compound and pharmaceutically acceptable salt
A compound defined as an amide structure, including a pharmaceutically acceptable salt thereof.
Substituted diamino/heteroaryl acetamide compound and pharmaceutically acceptable salt
A compound as defined in the disclosure, including a pharmaceutically acceptable salt thereof.
Pharmaceutical composition with the claimed compound
A pharmaceutical composition comprising the claimed compound, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable adjuvant, diluent, or carrier.
Treating selected conditions by administering the claimed compound
A method of treating a condition in a subject in need thereof by administering a therapeutically effective amount of the claimed compound, or a pharmaceutically acceptable salt thereof, wherein the condition is selected from the listed disease groups including cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, leukemia, skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, liver fibrosis, proteinuria, kidney graft rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, uveitis associated cystoid macular edema, retinopathy, diabetic retinopathy, and retinopathy of prematurity.
Porcupine-inhibition Wnt-signalling compounds
A compound which is chemical matter that modulates Wnt signalling by Porcn inhibition, or a pharmaceutically acceptable salt thereof.
Treating Porcn/Wnt-related conditions by administering the compound
A method of treating a condition in a subject in need thereof by administering a therapeutically effective amount of the compound or a pharmaceutically acceptable salt thereof, with the condition selected from the same enumerated disease groups.
The claim coverage centers on the defined compounds and salts, their pharmaceutical compositions, and therapeutic administration for the enumerated condition groups. The independent claims also include compound claims within the general formula framework and claims directed to Porcn inhibition and Wnt signalling modulation.
Stated Advantages
Improved properties including improved activity and solubility.
Reduced cytotoxicity.
Convenient PK.
GRAS metabolites.
Therapeutic use in enhancing anti-cancer treatment for Wnt-mediated conditions.
Documented Applications
Treatment of cancer, sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, carcinoma, and leukemia.
Treatment of skin fibrosis, idiopathic pulmonary fibrosis, renal interstitial fibrosis, liver fibrosis, proteinuria, kidney graft rejection, osteoarthritis, Parkinson's disease, cystoid macular edema, uveitis associated cystoid macular edema, retinopathy, diabetic retinopathy, and retinopathy of prematurity.
Wnt signalling modulation through Porcn inhibition.
Suppression of Wnt/beta-catenin signaling for secreted Wnt-ligand mediated diseases and cancers.
Treatment of cancer and Wnt-mediated anti-cancer therapeutic enhancement for conditions including sarcoma, melanoma, skin cancer, haematological tumors, lymphoma, and carcinoma.
Interested in licensing this patent?